vs
伯乐实验室（BIO）与Prenetics Global Ltd（PRE）财务数据对比。点击上方公司名可切换其他公司
伯乐实验室的季度营收约是Prenetics Global Ltd的161.4倍（$693.2M vs $4.3M）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
BIO vs PRE — 直观对比
营收规模更大
BIO
是对方的161.4倍
$4.3M
损益表 — Q4 2025 vs Q3 2023
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $4.3M |
| 净利润 | $720.0M | — |
| 毛利率 | 49.8% | 44.9% |
| 营业利润率 | -17.2% | -396.2% |
| 净利率 | 103.9% | — |
| 营收同比 | 3.9% | — |
| 净利润同比 | 200.6% | — |
| 每股收益（稀释后） | $26.59 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOPRE
| Q4 25 | $693.2M | — | ||
| Q3 25 | $653.0M | — | ||
| Q2 25 | $651.6M | — | ||
| Q1 25 | $585.4M | — | ||
| Q4 24 | $667.5M | — | ||
| Q3 24 | $649.7M | — | ||
| Q2 24 | $638.5M | — | ||
| Q1 24 | $610.8M | — |
净利润BIOPRE
| Q4 25 | $720.0M | — | ||
| Q3 25 | $-341.9M | — | ||
| Q2 25 | $317.8M | — | ||
| Q1 25 | $64.0M | — | ||
| Q4 24 | $-715.8M | — | ||
| Q3 24 | $653.2M | — | ||
| Q2 24 | $-2.2B | — | ||
| Q1 24 | $383.9M | — |
毛利率BIOPRE
| Q4 25 | 49.8% | — | ||
| Q3 25 | 52.6% | — | ||
| Q2 25 | 53.0% | — | ||
| Q1 25 | 52.3% | — | ||
| Q4 24 | 51.2% | — | ||
| Q3 24 | 54.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 53.4% | — |
营业利润率BIOPRE
| Q4 25 | -17.2% | — | ||
| Q3 25 | 10.0% | — | ||
| Q2 25 | 11.8% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | 9.9% | — | ||
| Q2 24 | 15.9% | — | ||
| Q1 24 | 7.3% | — |
净利率BIOPRE
| Q4 25 | 103.9% | — | ||
| Q3 25 | -52.4% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 10.9% | — | ||
| Q4 24 | -107.2% | — | ||
| Q3 24 | 100.5% | — | ||
| Q2 24 | -339.2% | — | ||
| Q1 24 | 62.9% | — |
每股收益（稀释后）BIOPRE
| Q4 25 | $26.59 | — | ||
| Q3 25 | $-12.70 | — | ||
| Q2 25 | $11.67 | — | ||
| Q1 25 | $2.29 | — | ||
| Q4 24 | $-25.89 | — | ||
| Q3 24 | $23.34 | — | ||
| Q2 24 | $-76.26 | — | ||
| Q1 24 | $13.45 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | — |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $7.5B | — |
| 总资产 | $10.6B | — |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
现金及短期投资BIOPRE
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
总债务BIOPRE
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BIOPRE
| Q4 25 | $7.5B | — | ||
| Q3 25 | $6.7B | — | ||
| Q2 25 | $7.1B | — | ||
| Q1 25 | $6.7B | — | ||
| Q4 24 | $6.6B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $9.1B | — |
总资产BIOPRE
| Q4 25 | $10.6B | — | ||
| Q3 25 | $9.7B | — | ||
| Q2 25 | $10.2B | — | ||
| Q1 25 | $9.5B | — | ||
| Q4 24 | $9.4B | — | ||
| Q3 24 | $10.6B | — | ||
| Q2 24 | $9.7B | — | ||
| Q1 24 | $12.6B | — |
负债/权益比BIOPRE
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | — |
| 自由现金流经营现金流 - 资本支出 | $119.1M | — |
| 自由现金流率自由现金流/营收 | 17.2% | — |
| 资本支出强度资本支出/营收 | 6.6% | — |
| 现金转化率经营现金流/净利润 | 0.23× | — |
| 过去12个月自由现金流最近4个季度 | $374.6M | — |
8季度趋势，按日历期对齐
经营现金流BIOPRE
| Q4 25 | $164.9M | — | ||
| Q3 25 | $120.9M | — | ||
| Q2 25 | $116.5M | — | ||
| Q1 25 | $129.9M | — | ||
| Q4 24 | $124.2M | — | ||
| Q3 24 | $163.6M | — | ||
| Q2 24 | $97.6M | — | ||
| Q1 24 | $69.8M | — |
自由现金流BIOPRE
| Q4 25 | $119.1M | — | ||
| Q3 25 | $89.2M | — | ||
| Q2 25 | $70.8M | — | ||
| Q1 25 | $95.5M | — | ||
| Q4 24 | $81.2M | — | ||
| Q3 24 | $123.4M | — | ||
| Q2 24 | $55.4M | — | ||
| Q1 24 | $29.6M | — |
自由现金流率BIOPRE
| Q4 25 | 17.2% | — | ||
| Q3 25 | 13.7% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 16.3% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 8.7% | — | ||
| Q1 24 | 4.8% | — |
资本支出强度BIOPRE
| Q4 25 | 6.6% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 5.9% | — | ||
| Q4 24 | 6.4% | — | ||
| Q3 24 | 6.2% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 6.6% | — |
现金转化率BIOPRE
| Q4 25 | 0.23× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
PRE
暂无分部数据
